Related references
Note: Only part of the references are listed.Metformin and Its Benefits for Various Diseases
Ziquan Lv et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Pharmacokinetic Interaction between Metformin and Verapamil in Rats: Inhibition of the OCT2-Mediated Renal Excretion of Metformin by Verapamil
Seung Yon Han et al.
PHARMACEUTICS (2020)
Genetics of diabetes mellitus and diabetes complications
Joanne B. Cole et al.
NATURE REVIEWS NEPHROLOGY (2020)
Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats
Agnieszka Karbownik et al.
PHARMACEUTICS (2020)
Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation
Aleksi Tornio et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Metformin in 2019
James Flory et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study
Li Wei et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population-based cohort study
Yu-Jui Kuo et al.
CANCER MEDICINE (2019)
The preventive effect of metformin on progression of benign prostate hyperplasia: A nationwide population-based cohort study in Korea
Yehee Hong et al.
PLOS ONE (2019)
Clinical Aspects of Transporter-Mediated Drug-Drug Interactions
Arne Gessner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
The anticancer potential of metformin on prostate cancer
Saher Zaidi et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2019)
Add-on Therapy With the α-Blockers Tamsulosin and Naftopidil Improves Voiding Function by Enhancing Neuronal Activity in Prostatic Hyperplasia Rats
Il-Gyu Ko et al.
INTERNATIONAL NEUROUROLOGY JOURNAL (2018)
Transporters Involved in Metformin Pharmacokinetics and Treatment Response
Xiaomin Liang et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Mechanistic invitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine
Robert Elsby et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2017)
Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions
H. J. Burt et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects
Ivy H. Song et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2016)
THE ADDITIONAL EFFECTS OF ALPHA BLOCKER IN BPH RAT; EFFECT ON CNS AND PROSTATE VOLUME
Khae Hawn Kim et al.
JOURNAL OF UROLOGY (2016)
Benign prostatic hyperplasia
Bilal Chughtai et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Inhibitory effect of atenolol on urinary excretion of metformin via down-regulating multidrug and toxin extrusion protein 1 (rMate1) expression in the kidney of rats
Yan-rong Ma et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates
Kristina Hacker et al.
PLOS ONE (2015)
Metformin Use and Prostate Cancer Risk
Mark A. Preston et al.
EUROPEAN UROLOGY (2014)
Hyperglycemia and Insulin Resistance and the Risk of BPH/LUTS: an Update of Recent Literature
Benjamin N. Breyer et al.
CURRENT UROLOGY REPORTS (2014)
Organic Cation Transporter OCTs (SLC22) and MATEs (SLC47) in the Human Kidney
Hideyuki Motohashi et al.
AAPS JOURNAL (2013)
Renal Transporters in Drug Development
Kari M. Morrissey et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 53, 2013 (2013)
The Effect of Novel Promoter Variants in MATE1 and MATE2 on the Pharmacokinetics and Pharmacodynamics of Metformin
S. L. Stocker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Clinical Pharmacokinetics of Metformin
Garry G. Graham et al.
CLINICAL PHARMACOKINETICS (2011)
Pharmacokinetics and Pharmacodynamics of Tamsulosin in its Modified-Release and Oral Controlled Absorption System Formulations
Gabriela Franco-Salinas et al.
CLINICAL PHARMACOKINETICS (2010)
Metabolic factors associated with benign prostatic hyperplasia
J. Kellogg Parsons et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Share Paper
